GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimerix Inc (STU:CXF) » Definitions » Shiller PE Ratio

Chimerix (STU:CXF) Shiller PE Ratio : (As of Jun. 23, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Chimerix Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Chimerix Shiller PE Ratio Historical Data

The historical data trend for Chimerix's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimerix Shiller PE Ratio Chart

Chimerix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Chimerix Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Chimerix's Shiller PE Ratio

For the Biotechnology subindustry, Chimerix's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chimerix's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chimerix's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Chimerix's Shiller PE Ratio falls into.



Chimerix Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Chimerix's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Chimerix's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.23/131.7762*131.7762
=-0.230

Current CPI (Mar. 2024) = 131.7762.

Chimerix Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.287 100.560 -0.376
201409 -0.365 100.428 -0.479
201412 -0.422 99.070 -0.561
201503 -0.499 99.621 -0.660
201506 -0.526 100.684 -0.688
201509 -0.624 100.392 -0.819
201512 -0.753 99.792 -0.994
201603 -0.512 100.470 -0.672
201606 -0.347 101.688 -0.450
201609 -0.330 101.861 -0.427
201612 -0.303 101.863 -0.392
201703 -0.355 102.862 -0.455
201706 -0.320 103.349 -0.408
201709 -0.310 104.136 -0.392
201712 -0.346 104.011 -0.438
201803 -0.341 105.290 -0.427
201806 -0.334 106.317 -0.414
201809 -0.283 106.507 -0.350
201812 -0.255 105.998 -0.317
201903 -0.310 107.251 -0.381
201906 -0.310 108.070 -0.378
201909 -1.144 108.329 -1.392
201912 -0.054 108.420 -0.066
202003 -0.154 108.902 -0.186
202006 -0.142 108.767 -0.172
202009 -0.153 109.815 -0.184
202012 -0.156 109.897 -0.187
202103 -1.016 111.754 -1.198
202106 -0.174 114.631 -0.200
202109 -0.179 115.734 -0.204
202112 -0.398 117.630 -0.446
202203 -0.254 121.301 -0.276
202206 -0.255 125.017 -0.269
202209 2.778 125.227 2.923
202212 -0.227 125.222 -0.239
202303 -0.224 127.348 -0.232
202306 -0.194 128.729 -0.199
202309 -0.253 129.860 -0.257
202312 -0.193 129.419 -0.197
202403 -0.230 131.776 -0.230

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Chimerix  (STU:CXF) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Chimerix Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Chimerix's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Chimerix (STU:CXF) Business Description

Traded in Other Exchanges
Address
2505 Meridian Parkway, Suite 100, Durham, NC, USA, 27713
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through license agreements and a federal contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for research and advanced development of drugs to treat various human diseases. The company operates only in one business segment namely pharmaceuticals.

Chimerix (STU:CXF) Headlines

No Headlines